返回

Drug price reform drives Korean pharma firms toward certification to delay 45% cuts

正在验证中
  • Small and medium-sized pharmaceutical companies are pursuing innovative and quasi-innovative certifications.
  • 45% is the government’s final generic and post-patent drug price calculation rate.
  • Ministry applications opened August 18 and close September 18, with about 100 companies expected to apply.
本网站上的信息是使用AI生成的，我们无法保证其准确性。 请仅作为参考信息使用。